{"title":"非扎他单抗在抗体介导的排斥反应中的应用","authors":"","doi":"10.1056/nejmc2409970","DOIUrl":null,"url":null,"abstract":"To the Editor: The trial by Böhmig and colleagues (July 11 issue)1 of felzartamab for the treatment of antibody-mediated rejection in kidney allografts showed promising results. However, notable li...","PeriodicalId":96,"journal":{"name":"Organic & Biomolecular Chemistry","volume":null,"pages":null},"PeriodicalIF":2.9000,"publicationDate":"2024-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Felzartamab in Antibody-Mediated Rejection\",\"authors\":\"\",\"doi\":\"10.1056/nejmc2409970\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"To the Editor: The trial by Böhmig and colleagues (July 11 issue)1 of felzartamab for the treatment of antibody-mediated rejection in kidney allografts showed promising results. However, notable li...\",\"PeriodicalId\":96,\"journal\":{\"name\":\"Organic & Biomolecular Chemistry\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":2.9000,\"publicationDate\":\"2024-09-26\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Organic & Biomolecular Chemistry\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1056/nejmc2409970\",\"RegionNum\":3,\"RegionCategory\":\"化学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"CHEMISTRY, ORGANIC\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Organic & Biomolecular Chemistry","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1056/nejmc2409970","RegionNum":3,"RegionCategory":"化学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CHEMISTRY, ORGANIC","Score":null,"Total":0}
To the Editor: The trial by Böhmig and colleagues (July 11 issue)1 of felzartamab for the treatment of antibody-mediated rejection in kidney allografts showed promising results. However, notable li...